Comparison Chart ARS Pharmaceuticals, Inc.
Stocks
SPRY
US82835W1080
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 5.390 USD | -4.09% |
|
-6.59% | -53.73% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS PHARMACEUTICALS, INC. | Other Biotechnology & Medical Research | -4.09% | -6.59% | -53.73% | -49.63% | - | 559M |  |  | |
- Stock Market
- Stocks
- SPRY Stock
- Charts ARS Pharmaceuticals, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
